COMMON STOCK PURCHASE WARRANT OXIS INTERNATIONAL, INC.Oxis International Inc • March 13th, 2015 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ___________________ ; or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the date that the Company has reserved from its authorized and unissued shares of Common Stock such aggregate number of shares of Common Stock issuable upon the exercise in full of this Warrant (the “Termination Date”) but not thereafter, to subscribe for and purchase from OXIS International, Inc., a Delaware corporation (the “Company”), up to 10,000,000 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock; provided, however, in the event that the number of shares of Common Stock reserved for the issuance of the Warrant Shares is less than the maximum number of Warr
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 13th, 2015 • Oxis International Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of DATE, between OXIS International, Inc., a Delaware corporation (the “Company”), and _________________________ identified on the signature pages hereto (including its successors and assigns, a “Purchaser” and collectively, the “Purchaser”).
10% SENIOR CONVERTIBLE DEBENTURE DUE MARCH______, 2017Oxis International Inc • March 13th, 2015 • Pharmaceutical preparations • New York
THIS 10% SENIOR CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued 10% Senior Convertible Debentures of OXIS International, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 4830 West Kennedy Blvd, Suite 600, Tampa, FL 33609, designated as its 10% Senior Convertible Debenture due March 3, 2017 (this debenture, the “Debenture” and, collectively with the other debentures of such series, the “Debentures”).
RESEARCH AGREEMENTResearch Agreement • March 13th, 2015 • Oxis International Inc • Pharmaceutical preparations • California
This RESEARCH AGREEMENT (the “Agreement”), effective as of March 10, 2015 (the “Effective Date”), is made by and between Oxis Biotech, Inc., a Delaware corporation, having a place of business at 1407 North Beverly Drive, Beverly Hills, CA 90210 (“OXIS”) and MultiCell Immunotherapeutics, Inc., a Delaware corporation, having a place of business at 68 Cumberland Street, Suite 301, Woonsocket, RI 02895 (hereinafter “MCIT”).
